Brezinschek H-P
Klinische Abteilung für Rheumatologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Auenbruggerplatz 15, 8036, Graz, Osterreich.
Z Rheumatol. 2008 Dec;67(8):653-4, 656-7. doi: 10.1007/s00393-008-0353-y.
Fibromyalgia syndrome (FMS) and myofascial pain syndrome (MPS) belong to the group of chronic non-inflammatory pain syndromes affecting muscles and tendinous insertions. Important criteria in the diagnosis of both diseases are the presence of "tender points" and "trigger points". According to ACR criteria FMS is characterized by the presence of tender points whereas trigger points are typically found in MPS.The main difference is that until now tender points could only be defined in terms of their localization, whereas trigger points can be found upon palpation which may cause a specific referred pain pattern. In addition, analysis of trigger points by microdialysis demonstrated elevated levels of pro-inflammatory substances at these sites. Moreover, local treatment of trigger points either by manipulative therapy or injection appears to be most effective for prompt relief of symptoms.
纤维肌痛综合征(FMS)和肌筋膜疼痛综合征(MPS)属于影响肌肉和肌腱附着点的慢性非炎性疼痛综合征。这两种疾病诊断的重要标准是存在“压痛点”和“触发点”。根据美国风湿病学会(ACR)标准,FMS的特征是存在压痛点,而触发点通常见于MPS。主要区别在于,到目前为止,压痛点只能根据其定位来定义,而触发点可通过触诊发现,触诊可能会引起特定的牵涉痛模式。此外,通过微透析对触发点进行分析表明,这些部位促炎物质水平升高。而且,通过手法治疗或注射对触发点进行局部治疗似乎对迅速缓解症状最为有效。